Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
FT576 in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant Treatment of Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
- Status
- COMPLETED
- Phase
- PHASE4
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2